U.S. Pet Medications at $8 Billion: Packaged Facts Report

U.S. retail sales of pet medications reached $8 billion in 2013, including sales through veterinarians, brick-and-mortar retailers, and online, according to “Pet Medications in the U.S.: Over-the-Counter and Prescription Remedies as Consumer Products, 3rd Edition,” a report by market research publisher Packaged Facts.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
The market will grow from its 2013 level to more than $10 billion in 2018, reflecting a CAGR of 5%.

Rockville, MD (PRWEB) April 02, 2014

U.S. retail sales of pet medications reached $8 billion in 2013, including sales through veterinarians, brick-and-mortar retailers, and online. This figure reflects a 2% increase over 2012 sales and a compound annual growth rate (CAGR) of 7% during the 2009-2013 period, according to “Pet Medications in the U.S.: Over-the-Counter and Prescription Remedies as Consumer Products, 3rd Edition,” a report by market research publisher Packaged Facts.

Growth in the overall pet medication category is attributable to the strength of several new product introductions, the return of Novartis products to the market (following the closure in 2012 of its Lincoln, NE plant), as well as continued strength of non-flea & tick drugs in the veterinary channel. By animal type, dogs accounted for the lion’s share of pet medication sales, at 77%, with cats representing the remainder.

Most marketers of pet medications in the U.S. slot into two groups: global pharmaceutical companies operating through animal health divisions and selling mainly through the veterinary channel, such as Merial; and pet product marketers selling through retail channels, including broad-line marketers like Central Garden & Pet and smaller companies focusing on over-the-counter pet health products. With the recent and ongoing cross-over into retail of formerly vet-only brands like Bayer’s Advantage and K9 Advantix, the pharmaceutical/veterinary vs. pet product/retail distinction is blurring, however. For many companies, antiparasitics are a key part of the pet medications portfolio, with flea/tick products representing their best-known consumer brands.

Looking to the future, Packaged Facts projects that pet medications sales will experience healthy returns through 2018. The market will grow from its 2013 level to more than $10 billion in 2018, reflecting a CAGR of 5%. As always, the biggest wildcard will be the weather for flea and tick sales. But as new products emerge in the coming years, the industry should be poised for healthy growth, notes Packaged Facts research director David Sprinkle.

For more information on “Pet Medications in the U.S.: Over-the-Counter and Prescription Remedies as Consumer Products, 3rd Edition,” please visit http://www.MarketResearch.com or http://www.packagedfacts.com/redirect.asp?progid=86053&productid=8014984.

About Packaged Facts – Packaged Facts, a division of MarketResearch.com, publishes market intelligence on a wide range of consumer market topics, including consumer demographics and shopper insights, consumer financial products and services, consumer goods and retailing, consumer packaged goods, and pet products and services. Packaged Facts also offers a full range of custom research services.

Please visit Packaged Facts on LinkedIn for more insights on pet products and services. Follow us also on Twitter, and Google+.


Contact

Follow us on: Contact's Twitter Contact's LinkedIn Contact's Google Plus